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Abstract
Introduction: Radioiodine (RAI) therapy is a standard procedure in the treatment of hyperthyroidism. However, the use of RAI in euthyroid 
patients requiring chronic administration of amiodarone (AM) where other antiarrhythmic drugs may lack efficacy is still controversial.
Objective: The aim of this study was to assess the safety and efficacy of an AM therapy prior to treatment with radioiodine therapy in 
euthyroid patients with permanent atrial fibrillation (PAF), who had been treated for hyperthyroidism in the past.
Material and methods: This was a retrospective observational study. Patients were assessed at baseline and two, six, eight, and 12 months 
after RAI therapy. 17 euthyroid patients with PAF were qualified to the RAI (female/male 3/14; age range 65 to 87, median 71). The patients 
required chronic administration of AM as a prophylaxis against sudden death.
Results: Each patient received an ablative dose of 800 MBq (22 mCi) of 131I. At baseline and during follow-up, no side effects of the therapy and 
no signs of drug intolerance were observed. Subclinical hyperthyroidism occurred in two (11.8%) cases after two months of RAI and five weeks 
of AM administration. In this situation, RAI therapy was repeated. Three patients (17.6%) after six months, and another two (11.8%) after eight 
months, required an additional dose of 131I due to amiodarone-induced thyrotoxicosis (AIT). Twelve patients (70.6%) returned to spontaneous 
sinus rhythm within two months. Fourteen patients (82.4%) had sinus rhythm during follow-up after six and 12 months of treatment.
Conclusions: Preventive RAI in euthyroid (but previously hyperthyroid) patients with PAF before administration of AM may be the 
method of choice. This is particularly important for patients who will require permanent AM administration as a life-saving drug. 
(Endokrynol Pol 2014; 65 (4):  269–274)
Key words: amiodarone-induced thyrotoxicosis; radioiodine therapy; permanent atrial fibrillation
Streszczenie
Wstęp: Terapia radiojodem (RAI) jest standardowym postępowaniem w leczeniu nadczynności tarczycy. Jednakże stosowanie RAI w stanie 
eutyreozy u pacjentów wymagających przewlekłego podawania amiodaronu (AM), w przypadku braku skuteczności innych leków przeciw-
arytmicznych, jest kontrowersyjne. Celem pracy była ocena bezpieczeństwa i skuteczności profilaktycznego zastosowania RAI, przed podaniem 
AM, u pacjentów w eutyreozie z utrwalonym migotaniem przedsionków (PAF), w przeszłości leczonych z powodu nadczynności tarczycy. 
Materiał i metody: przeprowadzono analizę retrospektywną. Chorych oceniano na początku badania oraz 2, 6, 8 i 12 miesięcy po zasto-
sowaniu RAI. 17 pacjentów z eutyreozą z towarzyszącym PAF zostało zakwalifikowanych do RAI (kobiety/ mężczyźni 3/14; wiek: 65–87, 
mediana 71 lat). Pacjenci wymagali przewlekłego stosowania AM jako profilaktyki nagłego zgonu sercowego. 
Wyniki: Każdy pacjent otrzymał dawkę ablacyjną 131I {800 MBq (22 mCi)}. Po podaniu RAI, jak również w okresie obserwacji nie 
zaobserwowano powikłań. Subkliniczna nadczynność tarczycy wystąpiła w 2 przypadkach (11,8%) po 2 miesiącach od podania RAI 
i 5 tygodniach od włączenia AM. W tej sytuacji leczenie RAI przeprowadzono ponownie. Trzech pacjentów (17,6%) po 6 miesiącach oraz 
2 (11,8%) po 8 miesiącach wymagało podania dodatkowej dawki 131I z powodu nadczynności tarczycy indukowanej AM. Dwunastu 
pacjentów (70,6%), powróciło do spontanicznego rytmu zatokowego w ciągu dwóch miesięcy. Po 6 i 12 miesiącach leczenia 14 pacjentów 
(82,4%) wykazało rytm zatokowy w badaniu kontrolnym. 
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Introduction
Amiodarone (AM) belongs to the 3rd class of antiarrhyth-
mic drugs (AAD) according to Vaughan-Williams [1, 2]. 
However, it has some of the properties of classes I and II 
through inhibition of the inward sodium currents [1]. In 
addition, it has been used in atrial and ventricular tachyar-
rhythmias. AM treatment may be regarded as prophylaxis 
against sudden cardiac death [3]. To date, it is considered 
to be the best and the most widely used AAD [1, 4]. AM 
is particularly applicable in pharmacological control of 
AF, especially the maintenance of primary prevention of 
AF or conversion of AF to sinus rhythm [5]. Its use is not 
without a number of side effects such as severe toxicity of 
lung, liver, nerves, skin, and thyroid [6–9]. The mechanism 
of AM’s influence on the thyroid is not entirely known [10, 
11]. While amiodarone-induced hypothyroidism is not 
a clinical problem, hyperthyroidism (AIT, amiodarone-
induced thyrotoxicosis) still presents a difficult challenge 
even for a skilled endocrinologist [12, 13]. Due to the long 
half-life and accumulation in tissues [14, 15] hyperthyroid-
ism may develop over time of use, or many months after 
its withdrawal [10, 11]. AIT may lead to increased mortality, 
particularly in the elderly with left ventricular dysfunction 
[16]. Also, AIT is very explosive and very difficult to treat 
and other pharmacological agents should possibly be used 
concomitantly with therapy [17].
Treatment options of AIT include: antithyroid drugs 
(ATD) [12, 18, 19], glucocorticoids [12, 19, 20], iopanoic 
acid [21], thyroidectomy [22, 23] or radioiodine (RAI) 
therapy [24–27]. There is a need for the evaluation of a 
possible role of RAI in euthyroid patients with persistent 
atrial fibrillation (PAF) requiring AM as a drug of choice 
to control symptomatic ventricular arrhythmias, pri-
marily to prevent recurrence of ventricular tachycardia 
(VT) and ventricular fibrillation (VF).
The aim of this study was to assess the safety and 
efficacy of an AM therapy prior to treatment with 
radioiodine therapy in euthyroid patients with PAF, 
who had been treated for hyperthyroidism in the past.
Materiał and methods
Patient characteristics
We retrospectively analysed medical records of 17 eu-
thyroid patients (female/male 3/14; age range from 65 
to 87, median 71 years) with PAF and history of hyper-
thyroidism, monitored at the Outpatients Department 
of Endocrinology, Metabolism and Internal Medicine 
in Poznan. All patients were subjected to RAI and 
evaluated retrospectively in a one-year follow-up after 
inclusion of AM. The following data were recorded: 
age, gender, time of occurrence of PAF, aetiology of 
heart disease, previous antiarrhythmic therapy, family 
history of hyperthyroidism, and type and duration of 
therapy for hyperthyroidism in the past.
Cardiac status
In all patients, heart failure was diagnosed, NYHA class 
II in five and class III in 12 cases. The aetiology of PAF 
included: ischaemic heart disease (four patients), dilated 
cardiomyopathy (four patients), myocardial infarction 
(four patients), haemodynamically insignificant left-
side valve disease (excluding mitral valve stenosis; two 
patients) and idiopathic PAF (three patients). Eight pa-
tients were implanted with a cardioverter-defibrillator. 
The mean duration of PAF was 232.3 ± 128.4 days. The 
admitted patients with PAF were treated unsuccess-
fully with other AADs such as procainamide (class Ia), 
propafenone (class Ic), atenolol (class II), propranolol 
(class II), sotalol (class III), etc. Therefore in the whole 
group, AM was used as the treatment of choice because 
of the escalating and life-threatening tachyarrhythmias. 
Additionally, in the whole studied group, hs-CRP (high 
sensitivity C-reactive protein) levels were measured as 
a sensitive marker associated with an increased rate of 
cardiovascular disease and mortality [28, 29]. The hs-
CRP level (reference range < 3 mg/L) was determined 
with a highly sensitive latex-based immunoassay (Dade 
Behring; sensitivity 0.05 mg/L) [30]. Clinical characteris-
tics of the analysed population are presented in Table I.
Thyroid status
According to medical records reviewed before RAI ther-
apy, all patients had been treated by antithyroid drugs 
(ATDs) — thionamide derivatives of thiouracyil {PTU, 
propylthiouracil (Thyrosan [Sun-Farm]} and imidazole 
[MMI, thiamazole, Metizol (INC Polfa-Rzeszów)], in one 
case RAI with glucocorticoids was used (Table I). Fur-
thermore, in one patient, subtotal thyroidectomy was 
performed before the occurrence of hyperthyroidism. 
Twelve patients had a family history of hyperthyroid-
ism. Current hormonal profile was characterised by 
lower limit of normal serum thyrotropin (TSH) and 
proper range of free thyroxine (fT4) and free triiodothy-
ronine (fT3) concentrations as well as negative thyroid 
Wnioski: Prewencyjne zastosowanie RAI przed włączeniem AM u pacjentów w eutyreozie (w wywiadzie: nadczynność tarczycy) z PAF, 
gdy terapia innymi lekami antyarytmicznymi okazuje się nieskuteczna, może być rozważana jako metoda z wyboru. Jest to szczególnie 
ważne w przypadku pacjentów wymagających stałego podawania AM jako leku ratującego życie.  (Endokrynol Pol 2014; 65 (4):  270–274)
Słowa kluczowe: nadczynność tarczycy indukowana amiodaronem; leczenie jodem radioaktywnym; utrwalone migotanie przedsionków
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autoantibodies (Tg-Abs: thyroglobulin autoantibodies, 
TPO-Abs: thyroperoxidase autoantibodies, TSHR-Abs: 
autoantibodies to the thyrotropin receptor). The nor-
mal ranges for serum hormone concentrations in our 
laboratory were as follows: TSH: 0.27–4.2 µIU/mL, fT4: 
11.5–21.5 pmol/L, fT3:
 3.9–6.8 pmol/L, Tg-Ab: 10–115 
IU/mL, TPO-Ab: 0–34 IU/mL and TSHR-Abs: < 2 IU/L. 
Free T4, free T3, as well as TSH, were measured by the 
electrochemiluminescent method (Roche). Serum TSH 
concentration was measured with a third-generation 
sensitivity  ≤ 0.005 IU/mL. Serum Tg-Abs, TPO-Abs and 
TSHR-Abs were measured by RIA (Brahms).
Sonography, radioiodine uptake and scintigraphy
Thyroid ultrasonography was performed using an 
Aloka SSD-500 (Aloka, Tokyo, Japan) with a 7.5-MHz 
linear transducer. Thyroid volume was measured by 
ultrasonography and calculated using the ellipsoid 
model (width × length × thickness × 0.52 for each 
lobe) [31, 32]. In the whole group, CFDS (colour-flow 
Doppler sonography) was performed [33]. The thy-
roid scintiscan 30 min. after an i.v. administration of 
150 MBq of 99mTc [Nucline gamma camera (Mediso, Hun-
gary)] was performed in cases where thyroid nodules 
occurred. Thyroidal radioiodine uptake (RAIU) values 
were measured 5 and 24 h after the administration of 
a diagnostic dose (ca. 2MBq) of 131I. The thyroid scin-
tiscan showed lack of accumulation of isotope.
Treatment
Radioiodine
All patients received an identical therapeutic ablative 
dose of 131I [22mCi = 800 MBq] before initiation of AM 
treatment.
Amiodarone
In the whole studied group, AM was used in recurrent, 
symptomatic PAF after ineffective treatment with AAD 
and electrical cardioversion. Oral AM administration 
in all patients was started at about the same time, 3–6 
weeks after RAI therapy. In two (11.76%) cases, AM was 
administered initially as an intravenous 150 mg bolus. 
The average dose of AM was from 150 to 900 mg daily. 
The therapy was continued on an outpatient basis.
Study protocol
In all patients, serum TSH, fT4, fT3 and autoantibodies 
(Abs) concentrations were measured at baseline and 
two, six, eight and 12 months afterwards. Hypothy-
roidism was defined when serum TSH concentration 
increased above the normal range (with a concomitant 
decrease in serum free thyroid hormone concentra-
tions). The diagnosis of AIT was based on the follow-
ing criteria: history of AM medication for at least one 
Table I. Clinical and biochemical features of patients included 
in the study at baseline 
Tabela I. Charakterystyka kliniczna i biochemiczna badanej 
grupy podczas rocznej obserwacji
Age [year; median (range)]* 71 (65–87)
Sex (F/M) 3/14
Cardiac state
Mean duration of PAF [days, mean (sd)] 232.3 (128.4)
Aetiology (n, %): 
ischaemic heart disease 
cardioverter-defibrillator 
history of myocardial infarction 
idiopathic AF 
insignificant left-sided valve disease
 
4 (23.5) 
8 (47.0) 
2 ( 11.7) 
2 (11.7) 
1 (5.8)
Heart failure; NYHA class (n, %): 
II 
III
 
5 (29.4) 
12 (70.6)
Previous treatment for cardiac disease (n, %): 
AAD: 
 Class I a: procainamide 
 Class I b: lidocaine 
 Class I c: propanfenone 
 Class II: metoprolol 
 Bisoprolol 
 Atenolol  
 Propranolol  
 Class III: sotalol 
DCC:
 
 
2 (11.8) 
2 (11.8) 
9 (52.9) 
10 (58.8) 
6 (35.3) 
3 (17.6) 
5 (29.4) 
12 (70.6) 
14 (82.3)
Hs-CRP [mg/dL] 5.2 (2.9)
Thyroid state
Family history of hyperthyroidism (%) 12 (70.6)
Duration of hyperthyroidism in past [months; 
median (range)]
17 (8–112)
Previous treatment for hyperthyroidism (n, %) 
ATDs: 
 MMI 
 PTU 
oGCS 
Subtotal thyroidectomy 
RAI therapy
 
 
15 (88.2) 
2 (11.8) 
1 (5.8) 
2 (11.8) 
1 (5.8)
fT4 [pmol/L; mean (sd)] 18.3 (1.8)
fT3 [pmol/L; mean (sd)] 5.4 (0.9)
TSH [mU/L; mean (sd)] 0.3 (0.1)
TPO-Abs [IU/mL; mean (sd)] 48.8 (25.1)
Tg-Abs [IU/mL; mean (sd)] 33.8 (11.3)
TSHR-Abs [IU/L; mean (sd)] 0.7 (0.2)
Thyroid volume [mL/m2] 13.4
CFDS 0
Dose of radioiodine [MBq; mean (sd)] 800 (0.0)
RAIU [mean (sd)] % 
After 5 h 
After 24 h
 
12.0 (2.1) 
14.1 (3.5)
*All euthyroid patients with PAF (who had had hyperthyroidism in past) received at baseline 
the same dose of 800MBq (22 mCi) 131I. Data is expressed as mean(sd). Normal values 
in our laboratory were as follows: free T4: 11.5–21.5 pmol/L; free T3:
 3.9–6.8 pmol/L; TSH: 
0.27–4.2 µU/mL; TSHR-Abs: < 2 IU/L, TPO-Abs: 0–34 IU/mL and Tg-Abs: 10–115 IU/mL 
and: CRP ≤ 5.0 mg/dL. All patients had undetectable serum Tg-Ab, TPO-Ab, TSHR-Abs. 
Thyroid volume was measured by ultrasonography (normal values range to 19 for F and to 
25 ml for M). Abbreviations: F — female; M — male; PAF — permanent atrial fibrillation; 
AAD — antiarrhythmic drugs; HY — hyperthyroid, EU* — euthyroid typical for AIT (with 
normal range of fT3); TSH — thyroid stimulating hormone; fT4 — free tetraiodothyroxine; 
fT3 — free triiodothyronine; TPO-Abs — thyroperoxidase antibodies; TSHR-Abs — 
autoantibodies to the thyrotropin receptor; HsCRP — High sensitivity C-reactive protein; 
CFDS — colour flow Doppler sonography; ATDs — antithyroid drugs; MMI — methimazole; 
PTU — propylthiouracyl; oGCS — oral glucocorticoids; RAI — radioiodine therapy;  
DCC — direct cardiac cardioversion; SR — sinus rhythm 
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month, signs and symptoms of hyperthyroidism con-
firmed by increased fT4 and suppressed TSH levels that 
occurred during therapy, a negative titre of circulating 
thyroid Abs (Tg-Abs, TPO-Abs, TSHR-Abs), thyroid of 
normal or slightly increased volume without relevant 
nodules (≥ 1 cm) at conventional ultrasonography. Signs 
associated with thyroid opthalmopathy (Dalrymple’s 
sign, Kocher’s sign, von Graefe’s sign and Mobius sign) 
were negative in our group of patients.
The study protocol was approved by the Ethics 
Committee at the University of Medical Sciences in 
Poznan. After informing patients about the aim of the 
study and proposed treatment, written permission was 
obtained from each patient.
Statistical analysis
The calculations were performed using Statistica 
v. 10 from StatSoft. A P value under 0.05 was consid-
ered statistically significant. Statistical significance 
of changes in laboratory parameters were calculated 
using variance analysis test for dependent variables 
(if there was a normal distribution of variable) or 
Friedman test (in cases of a lack of normal distribu-
tion). If a result was statistically significant, Tukey’s 
test was used to identify results which differed sig-
nificantly from each other.
Results
Patient characteristics
The study group comprised 17 consecutive patients 
(female/male 3/14; aged from 65 to 87, median 71 years) 
with PAF, in whom AM was used to prevent life-threat-
ening tachyarrhythmias. All patients in the past had 
been treated due to recurrences of hyperthyroidism. 
The clinical and biochemical examination at baseline 
and during one-year follow-up are presented in Table 
I and Table II.
Results of thyroid status and serology
Each patient received an ablative dose of 800 MBq 
(22 mCi) of 131I. At baseline and during follow-up, 
no side effects of the therapy and no signs of drug 
intolerance were observed. Subclinical hyperthyroid-
ism occurred in two (11.8%) cases after two months 
of RAI and five weeks of AM administration. In this 
situation, RAI therapy was performed again. Addi-
tionally, three patients (17.6%) after six months, and 
two (11.8%) patients after eight months, required 
the administration of an additional dose of 131I due 
to AIT. It should be noted that in none of the patients 
clinical symptoms of hyperthyroidism were observed. 
This was due to the antiadrenergic action of AM on 
the thyroid gland. The mean results of RAIU (before 
RAI therapy) after 5 and 24 hours were 12.0% and 
14.1%, respectively.
At baseline and two, six, eight and 12 months after 
RAI, the changes in levels of fT4 and fT3 were not 
significant. The mean (± SD) serum fT4 and fT3 levels 
were: 18.3 ± 1.8 and 5.4 ± 0.9 pmol/L (before RAI), 18.5 
± 2.0 pmol/L and 5.6 ± 1.0 pmol/L (after two months), 
18.2 ± 4.9 pmol/L and 6.1 ± 2.1 pmol/L (six months), 
16.3 ± 5.6 pmol/L and 5.3 ± 1.1 pmol/L (eight months), 
and 14.6 ± 4.1 pmol/L and 4.6 ± 1.1 pmol/L (12 months), 
respectively. The values of serum TSH were: 0.3 ± 0.1 
at baseline, 0.6 ± 0.6 after two months, 1.4 ± 1.1 (six 
months), 1.4 ± 2.8 (eight months), and 4.2 ± 3.0 IU/mL 
(12 months). These changes were significant 
(P < 0.0001). Furthermore, TSH level after 12 months 
was significantly higher than those at baseline and 
after two and eight months. The TPO-Abs, Tg-Abs, 
and TSHR-Abs were within normal limits and did not 
change significantly during the period of observation 
(Table I and II). During 12-month follow-up, in seven 
(40.9%) patients, hypothyroidism was diagnosed and 
in all these cases L-thyroxine was administered; in an-
other two (11.8%) patients, subclinical hypothyroidism 
was noted.
Hs-CRP levels were slightly elevated and were not 
significantly different during follow-up. At the baseline 
the ultrasound of the thyroid gland showed deeply 
decreased and irregular echogenicity and slightly 
decreased gland size during one-year follow-up. The 
CFDS indicated completely reduced vascularisation.
Results of cardiac status
Twelve patients (70.6%) returned to spontaneous SR 
within two months. Fourteen patients (82.4%) had SR 
during control examination after six and 12 months 
of treatment (Table II). Repeated DCC (direct cardiac 
cardioversion) was performed in four (23.5%) patients: 
three (17.6%) after six months and one (5.8%) after eight 
months of follow-up. No complications were observed.
Additionally, in two patients after eight months 
of follow-up who developed hyperthyroidism, beta-
blocker (atenolol; mean dose 36.2 ± 13.4 mg/day) was 
administered. Therefore, all of these patients required 
an additional dose of 131I again. In none of the cases was 
sudden cardiac death observed. During the 12 months of 
follow-up, no side-effects of AM were observed (Table II). 
Hyperthyroidism that occurred during the observation 
did not deteriorate the patients’ clinical cardiac status.
Discussion
Among all available antiarrhythmic drugs (AADs), AM 
is the most effective and is used for short-term inpatient 
and outpatient therapy. Particularly it is necessary to 
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achieve sinus rhythm (SR) during defibrillation test-
ing in patients with PAF undergoing implantation of 
a cardioverter−defibrillator (ICD) [34, 35]. According 
to Lelakowski et al. [35], AF may adversely influence 
the inappropriately on ICD as VF and/or ventricular 
tachycardia, may occur damaging the ventricular defi-
brillation programme.
In our study, many of the patients had had an ICD 
aimed at the treatment of PAF when AADs were not 
effective. However, defibrillation may lead to SR restora-
tion which may be hazardous due to the increased risk 
of thromboembolic complications [35]. The efficacy of 
a direct cardioverter-defibrillator in patients with PAF is 
on average about 75% and varies between 60% and 90%. 
The final effect depends on the energy and the type of 
impulse used [36, 37]. AM seems to be the most validated 
among numerous AADs with documented properties of 
restoring SR [38, 39]. However, administration of AM in 
patients who previously developed hyperthyroidism is 
dangerous. Unfortunately, the side effects in severe AIT 
can even lead to death.
The RAIU values do not seem to have clinical signifi-
cance since patients were taking ‘ablative’ doses of RAI. 
However, its determination is very important in order 
to assess the efficiency of RAI in patients receiving AM. 
This medication causes almost complete reduction of 
RAIU (less than 1%) which is characteristic for Type II 
AIT. Although the value of RAI in AIT in this situation 
remains controversial, our prior studies confirmed the 
efficacy of RAI therapy in AIT with greatly reduced 
RAIU [26].
In our study, an ‘ablative’ dose of 800 MBq of 131I 
(22 mCi) was used, regardless of the size of the thyroid 
gland. However, Hermida [40] administered various 
doses of RAI from 370 to 740 MBq (10-20 mCi) depend-
ing on the thyroid volume. Despite the fact that at base-
line all patients were euthyroid, in five cases a second 
dose of RAI was required due to the development of AIT 
(Table II). In clinical practice, the maximum dose of 131I 
should be applied prior to AIT for a protective effect.
We are aware of the limitations of our study: first of 
all, there was no detailed analysis of cardiac examinations 
(e.g. echocardiography) during follow-up; secondly, the 
administration of an ablative dose of 131I in already eu-
thyroid patients may give rise to much controversy. We 
realise that the AM contains a large amount of iodide (39% 
iodine by weight) [13] and is often administered ‘blindly’, 
mostly in the emergency departments, which can result 
in severe complications. AIT is a dangerous condition, 
which is very difficult to treat. First of all it may worsen 
the underlying cardiac disease, e.g. affect the control of 
arrhythmias. Secondly, thyrotoxicosis can increase the 
metabolism of oral anticoagulants, which are essential 
in patients with PAF. Furthermore, early diagnosis can 
be very difficult, especially in elderly patients as AIT can 
show unusual clinical manifestations with atypical symp-
Table II. Clinical characteristics of the study group during one-year follow-up
Tabela II. Charakterystyka kliniczna grupy badanej podczas rocznej obserwacji
Time of observation  
during AM therapy (months)
2 6 8 12
Thyroid state (n, %) 
EU 
HYPO 
HYPER (= AIT)
 
15 (88.2) 
– 
2 (11.8)
 
14 (82.3) 
– 
3 (17.6)
 
12 (70.6) 
3 (17.6) 
2 (11.8)
 
8 (47.0) 
9 (52.9) 
–
fT4 [pmol/L; mean (sd)] 18.5 (1.9) 18.2 (4.9) 16.3 (5.6) 14.6 (4.1)
fT3 [pmol/L; mean (sd)] 5.6 (1.0) 6.1 (2.1) 5.3 (1.1) 4.6 (1.1)
TSH [mU/L; mean (sd)] 0.6 (0.6) 1.2 (1.0) 1.4 (2.8) 4.2 (3.0)
TPO-Abs [IU/mL; mean (sd)] 67.5 (35.6) 37.9 (24.5) 39.3 (22.8) 33.6 (23.1)
Tg-Abs [IU/mL; mean (sd)] 43.2 (23.5) 59.2 (22.4) 33.9 (21.3) 49.9 (21.8)
TSHR-Abs [IU/L; mean (sd)] 1.2 (0.3) 1.0 (0.5) 0.8 (0.4) 0.9 (0.7)
Hs-CRP [mg/dL; mean (sd)] 5.1 (2.7) 6.3 (2.1) 5.9 (2.5) 5.4 (2.8)
Thyroid volume [mL/m2] 13.4 12.1 10.3 9.2
Dose of radioiodine  
[800 MBq (22mCi); mean (sd)]
800 (0.0) 
22 (0.0)
800 (0.0) 
22 (0.0)
800 (0.0) 
22 (0.0)
–
Return SR (n, %) 12 (70.59) 14 (82.35) 13 (76.47) 14 (82.35)
DCC – 3 (17.6%) 1 (5.8%) –
Abbreviations: AM — amiodarone; EU — euthyroidism; HYPO — hypothyroidism; HYPER — hyperthyroidism; AIT — amiodarone-induced thyrotoxicosis; fT4 — free 
tetraiodothyroxine; fT3 — free triiodothyronine; TSH — thyroid stimulating hormone; TPO-Abs — thyroperoxidase antibodies; Tg-Abs — thyroglobulin antibodies; 
TSHR-Abs —autoantibodies to the thyrotropin receptor; Hs-CRP — High sensitivity-C-reactive protein; SR — sinus rhythm; CI — coincidence interval; DDC — direct 
cardiac cardioversion
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toms limited to depression, reduced appetite, apathy or 
general weakness.
Therefore, endocrinologists often suggest to car-
diologists that they should withdraw AM and replace 
it by another AAD. However, in these particular cases 
which are the subjects of our dissertation, while other 
AADs were already ineffective, AM was a life-saving 
drug and prevented sudden death.
According to Hermida et al. [40] and also our ob-
servation, taking into account the potential risk/benefit 
ratio of permanent AM administration, RAI prior to AM 
medication seems to be the only effective and adequate 
preventative treatment in such difficult clinical situa-
tions when AIT may occur. This is particularly important 
in the following situations: 1) unsuccessful treatment 
after all other AADs have been used; 2) life-threatening 
atrial and ventricular tachyarrhythmias; 3) prior docu-
mented episode of AIT [40].
It is essential to observe patients carefully before and 
during AM administration. In our opinion, thorough 
thyroid gland examination and serum TSH measure-
ment should be performed at least once a month in 
patients continuously receiving AM. Additionally, we 
would recommend fT4 and fT3 determinations no less 
than once every three months.
To summarise, our results demonstrate that preven-
tive RAI therapy before including AM in euthyroid 
patients (but with a history of hyperthyroidism), with 
atrial tachyarrhythmias when other AAD drugs are 
ineffective may be a method of choice.
This is particularly important for patients who will 
require permanent administration of AM as a life-saving 
drug. Additionally, it should be noted that the only 
‘complication’ after RAI therapy may be permanent 
hypothyroidism. However, in this particular clinical 
situation, hypothyroidism should be considered as a 
goal rather than the side effect of RAI therapy.
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